Enovis (ENOV) AI Stock Analysis

• Market Cap: $1.26B
• Dividend Yield: N/A
• Average Volume (3M): 883.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: 11.57%
• EPS Growth: -1016.39%
• Country: US
• Employees: 7,367
• Sector: Healthcare
• Sector Strength: 45
• Industry: Industrial - Machinery
• EPS (TTM): 0.75
• Shares Outstanding: 57,189,380
• 10 Day Avg. Volume: 921,789
• 30 Day Avg. Volume: 883,331
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.95
• Price to Sales (P/S): 1.15
• P/FCF Ratio: -36.09
• Enterprise Value/Market Cap: 2.15
• Enterprise Value/Revenue: 1.21
• Enterprise Value/Gross Profit: 2.08
• Enterprise Value/Ebitda: -2.73
• 1Y Price Target: $45.25
• Price Target Upside: 110.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $27.00 ▲(25.82% Upside)

The score is held back primarily by weak financial performance (negative profitability and concerning cash-flow trends) and a bearish technical backdrop (trading below key moving averages with negative MACD). Positives from the earnings call—raised profitability guidance, solid organic growth, and near-term free cash flow—plus improved financing flexibility partially offset these risks.

Positive Factors

Revenue & International Growth

Sustained reported and organic revenue growth, combined with 12% international expansion, indicates broad-based demand and successful cross‑selling after acquisitions. Durable geographic and segment diversification should support midterm top‑line resilience and revenue stability.

Product Innovation — Arvis Ultra

Clinical acceptance of Arvis Ultra and a planned broader launch signal durable product adoption potential. New device uptake can drive procedure share gains, higher ASPs and margin leverage over multiple quarters, strengthening the company’s competitive positioning in reconstructive devices.

Improved Financial Flexibility

Extended maturities, reduced borrowing margins potential, and eased covenant mechanics materially lower near‑term refinancing risk. Greater debt headroom and acquisition flexibility support longer‑term strategic execution and deleveraging without immediate liquidity strain.

Negative Factors

Persistent Profitability Weakness

Despite revenue growth, persistent negative EBIT/net margins and a negative ROE show the business struggles to convert sales into sustainable profits. Long‑term value creation depends on reversing structural margin gaps and improving operating efficiency across segments.

Weak Free Cash Flow Quality

Declining free cash flow growth and poor FCF-to-net‑income dynamics limit capacity to deleverage and finance R&D or M&A internally. Even with a quarter of positive FCF, inconsistent cash generation raises execution risk for strategic initiatives over the next several quarters.

Large Non‑cash Impairment & Near‑term Headwinds

A $548M goodwill write‑down reflects asset repricing and raises governance/valuation questions; tariffs and the Dr. Comfort divestiture create recurring margin and revenue pressure. These structural hits reduce balance‑sheet cushion and constrain medium‑term earnings recovery prospects.

Enovis Business Overview & Revenue Model

Company Description

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

How the Company Makes Money

Enovis generates revenue primarily through the sale of its orthopedic and rehabilitation products. Key revenue streams include sales from surgical devices, which are utilized in various orthopedic procedures, and the distribution of supportive products such as braces and rehabilitation equipment. The company also leverages digital health solutions that provide additional services and support to healthcare providers and patients. Significant partnerships with healthcare systems and providers enhance its market reach and contribute to its earnings, alongside continuous investments in research and development to innovate and expand its product offerings.

Enovis Financial Statement Overview

Summary

Revenue is growing modestly, and leverage is improving, but overall fundamentals are held back by negative profitability (negative net/EBIT margins and negative ROE) and weak free cash flow trends that raise liquidity and execution risk.

Income Statement

Enovis has shown a consistent increase in revenue over the years, with a TTM revenue growth rate of 1.995%. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin remains relatively stable, but the negative EBIT and EBITDA margins suggest operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio has improved significantly, indicating a reduction in leverage, which is a positive sign. However, the return on equity is negative, reflecting ongoing challenges in generating profits from shareholders' equity. The equity ratio is stable, suggesting a solid asset base relative to equity.

Cash Flow

Enovis's cash flow situation is concerning, with a significant decline in free cash flow growth. The operating cash flow to net income ratio is positive, but the free cash flow to net income ratio indicates that cash generation is not keeping pace with net losses. This could pose liquidity challenges if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.23B	2.11B	1.71B	1.56B	1.43B	1.12B
Gross Profit	1.30B	1.18B	990.78M	869.38M	777.67M	603.64M
EBITDA	-989.61M	-481.03M	169.73M	241.69M	170.25M	180.05M
Net Income	-1.37B	-825.49M	-33.26M	-13.29M	71.66M	42.63M
Balance Sheet
Total Assets	4.43B	4.72B	4.51B	4.27B	8.52B	7.35B
Cash, Cash Equivalents and Short-Term Investments	33.62M	48.17M	36.19M	24.30M	680.25M	101.07M
Total Debt	1.44B	1.40B	536.42M	334.82M	2.16B	2.41B
Total Liabilities	2.41B	2.15B	1.09B	823.45M	3.85B	3.76B
Stockholders Equity	2.02B	2.56B	3.42B	3.45B	4.62B	3.54B
Cash Flow
Free Cash Flow	22.77M	-67.21M	12.77M	-161.31M	251.86M	187.15M
Operating Cash Flow	217.08M	113.50M	134.99M	-55.86M	356.10M	301.94M
Investing Cash Flow	-224.26M	-955.47M	-242.47M	-176.39M	-320.48M	-175.08M
Financing Cash Flow	435.00K	846.82M	127.80M	-465.13M	584.91M	-131.65M

Enovis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENOV, the sentiment is Negative. The current price of 21.46 is below the 20-day moving average (MA) of 25.27, below the 50-day MA of 26.86, and below the 200-day MA of 30.32, indicating a bearish trend. The MACD of -1.48 indicates Positive momentum. The RSI at 28.31 is Positive, neither overbought nor oversold. The STOCH value of 4.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENOV.

Enovis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SXI	73 Outperform	$2.97B	56.17	7.72%	0.57%	18.51%	-28.69%
EPAC	68 Neutral	$2.11B	23.94	21.75%	0.10%	3.91%	1.48%
HLIO	67 Neutral	$2.18B	64.92	3.75%	0.64%	-1.46%	-10.03%
HI	65 Neutral	$2.25B	52.40	3.07%	2.85%	-16.00%	―
XMTR	55 Neutral	$3.34B	-51.98	-21.46%	―	22.40%	-18.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENOV	49 Neutral	$1.26B	-0.89	-51.11%	―	11.57%	-1016.39%

Enovis Corporate Events

Enovis to Present at J.P. Morgan Healthcare Conference

Enovis Corporation announced that its management team would present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PST (7:30 p.m. EST). The company made the presentation accessible to investors and other stakeholders via a live webcast on its website, with a replay and accompanying presentation materials also made available online later that day, underscoring Enovis’s ongoing investor-relations outreach and engagement with the healthcare investment community.

The most recent analyst rating on (ENOV) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Enovis stock, see the ENOV Stock Forecast page.

Enovis Announces Leadership Transition in HR Department

On December 10, 2025, Enovis Corporation announced that Patricia A. Lang will retire from her role as Senior Vice President and Chief Human Resources Officer on April 3, 2026, transitioning to an advisory role until her full retirement on April 3, 2027. Laura Singleton, currently Vice President of Human Resources for the Reconstructive segment, will succeed Lang. Singleton, who joined Enovis in 2019, has extensive experience in human resources leadership roles. The company has entered into a retirement transition agreement with Lang, ensuring her continued contribution in a non-executive role during the transition period, with adjustments to her salary and benefits.

The most recent analyst rating on (ENOV) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Enovis stock, see the ENOV Stock Forecast page.

Enovis Amends Credit Agreement for Financial Flexibility

On December 8, 2025, Enovis Corporation amended its existing credit agreement to enhance its financial flexibility. The amendment extends the maturity date for its revolving and term loan facilities to December 8, 2030, and allows for increased cash offsets in leverage ratio calculations. The amendment also reduces borrowing margins under certain conditions and modifies covenants to allow for greater acquisition spending and debt capacity. New lenders joined the agreement, and part of the term loan proceeds was used to repay existing revolving debt.

The most recent analyst rating on (ENOV) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Enovis stock, see the ENOV Stock Forecast page.

Enovis Announces Executive Vice President’s Departure

On November 7, 2025, Enovis Corporation announced that Daniel A. Pryor would step down from his role as Executive Vice President, Strategy and Business Development, as part of a management restructuring. Mr. Pryor will remain with the company in an advisory role until March 31, 2026, and will receive his current salary and benefits until his departure. The restructuring involves a termination without cause under his employment agreement, and he will receive a cash bonus for 2025, continued vesting of equity awards, and other benefits as outlined in the Separation Agreement.

The most recent analyst rating on (ENOV) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Enovis stock, see the ENOV Stock Forecast page.